Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

*Carcinoma Transitional Cell/drug therapy/pathology Cisplatin Female Humans Male *Urinary Bladder Neoplasms/drug therapy/pathology *Urology *Bladder cancer *European Association of Urology *Guidelines *Immunotherapy *Metastatic *Systemic therapy *Urothelial carcinoma

Administration Intravesical BCG Vaccine/therapeutic use Humans Neoplasm Recurrence Local/prevention & control Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Intermediate risk Intravesical therapy Non–muscle-invasive bladder cancer

Administration Intravesical Antineoplastic Agents/*pharmacology Humans Maintenance Chemotherapy/*methods Neoplasm Invasiveness Neoplasm Recurrence Local/*prevention & control Prognosis Randomized Controlled Trials as Topic Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Chemotherapy Intravesical Maintenance